FB-102
- Generic Name
- FB-102
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FB102 IN ADULT WITH CELIAC DISEASE
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Forte Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06982963
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Forte Biosciences, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06905873
- Locations
- 🇦🇺
Skin & Cancer Foundation Australia - The Skin Hospital, Darlinghurst, New South Wales, Australia
🇦🇺Novatrials, Kotara, New South Wales, Australia
🇦🇺Cornerstone Dermatology, Coorparoo, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath